Mallya

Novo Nordisk Enters Into Exclusive Negotiations to Acquire a Controlling Stake in BICORP, to Be Followed by a Tender Offer on All Remaining Shares.

Retrieved on: 
Monday, June 5, 2023
Medical Devices, Health, Diabetes, Research, Science, Biotechnology, Prejudice, McDermott Will & Emery, BIO, Insulin, Obesity, ALCOR, Sale, EUR, Bird & Bird, Documentation, Acquisition, Lazard, Patient, Blood, AMF, Conditional sentence, Device, Security (finance), Pharmaceutical industry, Management, Stifel, Nordisk, Euronext, Novo Nordisk, Mallya

“We are delighted by the potential to join Novo Nordisk, a leading global healthcare company.

Key Points: 
  • “We are delighted by the potential to join Novo Nordisk, a leading global healthcare company.
  • Our teams are enthusiastic about pursuing this public health mission, which will be intensified by the strength of Novo Nordisk's global presence” said Eric Dessertenne, CEO of BIOCORP.
  • Novo Nordisk employs about 57,100 people in 80 countries and markets its products in around 170 countries.
  • 3 On the basis of a share capital as at 31 May 2023 of 4,412,286 actions representing 6,427,898 theoretical voting rights.

BIOCORP Obtains 510(k) FDA Clearance for Mallya®

Retrieved on: 
Wednesday, December 7, 2022
Health, FDA, Medical Devices, Diabetes, Health Technology, Pharmaceutical, Biotechnology, Insulin, IIB, Patient, Sale, FDA, Diabetes, News, Record, CE, Medical device, Pharmaceutical industry, Euronext, Mallya

Eric Dessertenne, CEO of BIOCORP, said: "This approval is a major achievement for BIOCORP and all of our employees who have been heavily involved in this regulatory process.

Key Points: 
  • Eric Dessertenne, CEO of BIOCORP, said: "This approval is a major achievement for BIOCORP and all of our employees who have been heavily involved in this regulatory process.
  • This approval marks a historic achievement for BIOCORP as it allows the commercial launch of our Mallya device in the United States and illustrates BIOCORP's ability to meet the highest regulatory requirements.
  • The Mallya medical device is a smart sensor that is directly attached to insulin pen injectors, making them connected devices.
  • Mallya is already the only device in its class to be CE marked as a Class IIb medical device.

BIOCORP and NOVO NORDISK Strengthen Their Partnership With a New Agreement on Mallya® Smart Sensor

Retrieved on: 
Wednesday, October 26, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Medical Devices, Clinical Trials, Time, Sale, Technology, Novo Nordisk, Patient, Partnership, MD, CEO, Diabetes, Journal, Insulin, ALCOR, Solution, Compliance, Pharmaceutical industry, Medical device, Euronext, Mallya

This new agreement is reinforcing the partnership between Novo Nordisk and BIOCORP focused on development of the Mallya product announced in September 2021.

Key Points: 
  • This new agreement is reinforcing the partnership between Novo Nordisk and BIOCORP focused on development of the Mallya product announced in September 2021.
  • Mallya (a non-medical device in Japan) is a smart sensor that directly attaches to the Novo Nordisk FlexTouch insulin pens.
  • Mallya is compatible with all Novo Nordisk FlexTouch insulin pens.
  • Based on the agreement, Novo Nordisk will be commercializing Mallya in Japan from the first half of 2023.

BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs

Retrieved on: 
Tuesday, October 18, 2022
Medical Supplies, Medical Devices, Health, Health Technology, Pharmaceutical, Biotechnology, NFC, LinkedIn, Near-field communication, Disease, Therapy, Sale, Syringe, Prevalence, Efficiency, Smartphone, BDX, Organization, NYSE, Patient, Twitter, Technology, Compliance, Company, Becton, Dickinson and Company headquarters, Health, CEO, Conditional sentence, Safety, Diabetes, Becton, ALCOR, Solution, View, Pharmaceutical industry, Euronext, Mallya

Biocorps Injay is a simple and cost-effective connected solution designed to monitor the use of pre-fillable syringes in clinical studies or routine care.

Key Points: 
  • Biocorps Injay is a simple and cost-effective connected solution designed to monitor the use of pre-fillable syringes in clinical studies or routine care.
  • We are very proud to announce this collaboration with BD, a worldwide leader in pre-filled syringes and safety device market, said Eric Dessertenne, CEO of Biocorp.
  • It shows the leading position of Biocorp in the field of smart drug delivery devices and addresses an unmet need in the market today.
  • Includes both BD UltraSafe Passive and BD UltraSafe Plus passive needle guards
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221017006035/en/

BIOCORP and Merck KGaA, Darmstadt, Germany, Sign a New Partnership for Smart Drug Delivery

Retrieved on: 
Monday, October 10, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Diabetes, Medical Devices, Clinical Trials, Adoption, Time, Merck, Sale, Health care, Patient, Partnership, Technology, HGH, CEO, Diabetes, Merck Group, Growth hormone, ALCOR, Solution, Compliance, Pharmaceutical industry, Euronext, Insulin, Mallya

Major agreements have already been signed by BIOCORP with Sanofi, Novo Nordisk and Merck KGaA, Darmstadt, Germany, to develop specific versions of the technology in the field of Insulin and Human Growth Hormone (HGH).

Key Points: 
  • Major agreements have already been signed by BIOCORP with Sanofi, Novo Nordisk and Merck KGaA, Darmstadt, Germany, to develop specific versions of the technology in the field of Insulin and Human Growth Hormone (HGH).
  • Healthcare companies BIOCORP and Merck KGaA, Darmstadt, Germany, will develop a new version of Mallya to help patients monitor their injection during their treatment.
  • Financial details of the partnership include payments from Merck KGaA, Darmstadt, Germany, up to 5 million for the development of the product within the first three years of the collaboration.
  • "We are delighted with this new partnership with Merck KGaA, Darmstadt, Germany, extending our collaboration to additional therapeutic areas.

BIOCORP announces the CE marking of SoloSmart®, an accessory medical device for SANOFI Solostar® pens at the occasion of EASD

Retrieved on: 
Monday, September 19, 2022
Diabetes, Pharmaceutical, Health, Medical Devices, Time, D, Sale, BGM, European Association for the Study of Diabetes, Compliance, Partnership, Patient, CEO, Solution, Record, EASD, Sanofi, Pharmaceutical industry, Medical device, Mallya, Diabetes, Euronext

SoloSmart is fully compatible with the pharmaceutical group's SoloStar injection pens.

Key Points: 
  • SoloSmart is fully compatible with the pharmaceutical group's SoloStar injection pens.
  • Developed by BIOCORP's R&D department, SoloSmart meets the latest requirements of the new European medical device regulation.
  • Its commercial launch will begin early 2023 in the distribution networks approved by SANOFI and its partners.
  • Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya.

Health2Sync Expands Product Offering in Chronic Disease Management with Real Word Data Integration and Analytics

Retrieved on: 
Tuesday, January 18, 2022
Ministry, Patient, Health status of Asian Americans, Ministry of Health (Saudi Arabia), Insulin, Exercise, Healthline, Sanofi, Partnership, Support, CEO, Degenerative disease, Disease, Solution, Severe cognitive impairment, Diet, Astellas Pharma, Diabetes, Single-frequency network, Disease management, View, Industry, Blood pressure, Ecosystem, Triage, Chronic kidney disease, Goal, Fitbit, FreeStyle, Blood, Efficiency, Glycated hemoglobin, Conditional sentence, Multimedia, Risk, Communication, CGM, Decision-making, Software, Amputation, Dialysis, Hospital, Novo Nordisk, Physician, Policy, Medical device, Pharmaceutical industry, Health insurance, Mallya, Health

The Health2Sync app allows individuals to visualize personal information regarding CGM statistics, blood pressure, diet, exercise, and weight.

Key Points: 
  • The Health2Sync app allows individuals to visualize personal information regarding CGM statistics, blood pressure, diet, exercise, and weight.
  • The cloud-based data analytics program also enables improved patient management efficiency and decision making, comorbidity tracking, triage, and bi-directional communication.
  • "Health2Sync solves the disconnect in traditional chronic disease management," said Ed Deng, Co-founder and CEO of Health2Sync.
  • Established in 2013, Health2Sync aims to provide personalized and scalable digital solutions for chronic disease patients.

BIOCORP Signs New Partnership Around InspairTM With H&T Presspart

Retrieved on: 
Thursday, December 16, 2021
Biotechnology, General Health, Medical Devices, Other Health, Health, Solution, Harry Thumann, Respiratory disease, IPTC, Sale, National Association Medical Staff Services, ALCOR, Heitkamp, CEO, Inhalation, Patient, COPD, Chronic obstructive pulmonary disease, Partnership, Diabetes, Asthma, Compliance, Pharmaceutical industry, Mallya, Euronext, U.S.A

This partnership will allow BIOCORP to integrate its connected solution with the most popular inhalers on the market, while leveraging its partner's extensive sales network to distribute InspairTM.

Key Points: 
  • This partnership will allow BIOCORP to integrate its connected solution with the most popular inhalers on the market, while leveraging its partner's extensive sales network to distribute InspairTM.
  • Christian Kraetzig, President of H&T Presspart commented: This strategic partnership underlines our commitment to forging alliances that accelerate the development, global scale-up and commercialisation of novel drug delivery solutions for patients.
  • Eric Dessertenne, CEO of BIOCORP added: "We are very proud to entrust the distribution of InspairTM to H&T Presspart, one of the world leaders in the respiratory disease market.
  • After our success with MallyaTM, BIOCORP now has a second solution with very high potential both in terms of business and the number of possible applications with InspairTM.

BIOCORP Signs Two New Partnerships With Mallya Technology

Retrieved on: 
Wednesday, February 17, 2021
Other Health, Software, Managed care, General Health, Data management, Medical devices, Technology, Hospitals, Fitness & Nutrition, Biotechnology, Health, Diabetes, Injector pen, Medical equipment, Mallya, Medicine, Insulin, Clinical medicine, Pharmacology

These two partnerships involve the integration of Mallya, the connected device dedicated to insulin pens, with the digital applications developed by Health2Sync and SocialDiabetes to improve the quality of care for patients with diabetes.

Key Points: 
  • These two partnerships involve the integration of Mallya, the connected device dedicated to insulin pens, with the digital applications developed by Health2Sync and SocialDiabetes to improve the quality of care for patients with diabetes.
  • ric Dessertenne, CEO of BIOCORP, explained: These new partnerships come at a time when our teams are preparing for the large-scale commercial launch of Mallya, which is already compatible with almost all disposable pens on the market.
  • Mallya sensor is a world-class player and represents the type of high-quality technology we want to bring to our customers.
  • Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions.

BIOCORP and SANOFI Strengthen Their Partnership With Mallya Smart Sensors

Retrieved on: 
Tuesday, January 14, 2020
Technology, Biotechnology, Health, Finance, Other Health, Professional services, Other Technology, Medical devices, Managed care, General Health, Hospitals, Genetics, Cardiology, Medical Supplies, Eli Lilly and Company, Medicine, Companies, Sanofi, Insulin pen, Mallya, Insulin, Alcor, Life sciences

BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, and SANOFI announce today, the signature of a new contract concerning BIOCORPs smart sensor Mallya.

Key Points: 
  • BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, and SANOFI announce today, the signature of a new contract concerning BIOCORPs smart sensor Mallya.
  • Negotiations started in July 2019 have led the BIOCORP and SANOFI teams to strengthen their collaboration, developing real synergies around the Mallya system.
  • A new project aiming at closely associating Mallya with SoloStar insulin pens is thus initiated today.
  • Additional revenues will be generated from the production of Mallya devices by BIOCORP on behalf of SANOFI.